Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Drug-induced extrapyramidal symptoms (Orphenadrine hydrochloride - Drug-induced extrapyramidal symptoms)

Records returned : 6 (on 17 Jul 2025 at 07:41:48). Return to search results for ' Drug-induced extrapyramidal symptoms '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Status :
Non Formulary
Restrictions / Comments:

 
Links :
NFD1
Status :
Blue
Formulations :
  • Intramuscular injection (IM)
  • Intravenous injection (IV)
  • Tablets
Restrictions / Comments:

Important

PALLIATIVE CARE - Primary Care prescribing on advice from palliative care specialist team.

 
Links :
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option.

See PAD for additional safety advice.

 
Links :
SPC
Status :
Blue
Formulations :
  • Oral solution
Restrictions / Comments:

Important

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option. Reserve oral solution for patients unable to swallow the tablets.

See PAD for additional safety information.

 
Links :
SPC
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

Procyclidine tablets are the preferred treatment option.

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Antimuscarinics should not be used in tardive dyskinesia

Recommendation for use to be made by SABP specialist only after consideration and trial of reduction of antipsychotic dose has occured or alternative treatment options have first been tried.
See PAD for additional safety advice.

 
Links :
SPC
Status :
Blue
Formulations :
  • Oral solution
Restrictions / Comments:

Important

SABP specialist initiation and stabilisation for at least one month before any request for transfer of prescribing responsibility.

Tablets are the preferred treatment option. Reserve oral solution for patients unable to swallow the tablets.

Recommendation for use to be made by SABP specialist only after consideration and trial of reduction of antipsychotic dose has occured or alternative treatment options have first been tried.

See PAD for additional safety information.

 
Links :
SPC